Redirecting to https://www.prnewswire.com/news-releases/dizal-announces-positive-topline-phase-3-results-from-wu-kong28-study-evaluating-oral-once-daily-zegfrovy-sunvozertinib-vs-platinum-containing-chemo-doublet-in-first-line-non-small-cell-lung-cancer-nsclc-with-egfr-exon-20--302721366.html